Ophthalmic Solution

TearClear has initiated a phase 3 trial evaluating TC-002, a preservative-free latanoprost ophthalmic solution, in patients with glaucoma, according to a press release.

Three topical ophthalmic formulations designed to treat presbyopia demonstrated positive results in the phase 2 VIVID clinical trial, Visus Therapeutics announced in a press release.

BOSTON – Orasis Pharmaceuticals anticipates finishing its phase 3 program involving CSF-1 ophthalmic solution for treating presbyopia this year, President and COO Paul Smith said here at the American Academy of Optometry meeting.

Aerie Pharmaceuticals has completed enrollment in a phase 3 trial in Japan investigating netarsudil in patients with primary open-angle glaucoma or ocular hypertension, according to a press release.

In corneal cross-linking, the cornea is saturated with a photosensitizing drug that is activated by UVA light to strengthen and stiffen collagen bonds.

The results of the Atlas study, presented at the virtual Association for Research in Vision and Ophthalmology meeting, show the functional and psychosocial impact Demodex blepharitis has on patients, according to a Tarsus press release.

SAN FRANCISCO — Elad Kedar, CEO of Orasis Pharmaceuticals, discusses results of a phase 2b trial of the company’s CSF-1 eye drop formulation for presbyopia correction at the Ophthalmology Innovation Summit preceding the American Academy of Ophthalmology annual meeting. Positive safety, durability and efficacy results were demonstrated, he said.